Trial of Romidepsin and Bortezomib for Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib With Melphalan and Prednisone for Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia
- Status
- WITHDRAWN
- Phase
- PHASE2
The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates
- Status
- COMPLETED
- Phase
- PHASE2
Natural Killer Cells and Bortezomib to Treat Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation
- Status
- COMPLETED
- Phase
- PHASE1